We would like to express gratitude to the patient and our members of the COVID-19 team in Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. Publication charges for this article were waived due to the ongoing pandemic of COVID-19.
Wu Z, McGoogan JM, 2020. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323: 1239–1242.
Zhang L et al. 2020. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 31: 894–901.
Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H, 2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 5: 33.
Bersanelli M, 2020. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy 12: 269–273.
Wu C et al. 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180: 1–11.
Russell CD, Millar JE, Baillie JK, 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395: 473–475.
Dondorp AM, Hayat M, Aryal D, Beane A, Schultz MJ, 2020. Respiratory support in novel Coronavirus disease (COVID-19) patients, with a focus on resource-limited settings. Am J Trop Med Hyg 102: 1191–1197.
National Institutes of Health, 2020. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov. Accessed July 31, 2020.